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Oral mucositis induced by radiotherapy for cancers of the head and neck reduce the quality of life of
patients. However, effective therapeutic agents are lacking. Symptomatic treatment involves local
anesthesia and analgesia. We focused on the antioxidant effects of edaravone (3-methyl-1-phenyl-2-
pyrazolin-5-one; Radicut®). Oral mucositis was induced on the tongue tips of mice using a single dose
of X-rays (20 Gy). To evaluate the protective effect of edaravone (30 and 300 mg/kg), administration was
carried out 30 min before irradiation. Survival, oral mucositis score, myeloperoxidase activity, and levels
of 2-Thiobarbituric acid reactive substances were measured, and all were improved compared with those
of control mice. A signiﬁcant difference was not found in terms of survival due to edaravone. Histo-
pathologic ﬁndings also highlighted the beneﬁcial features of edaravone. Edaravone reduced the pro-
duction of reactive oxygen species. These ﬁndings suggest that the protective effect of edaravone against
radiation-induced oral mucositis is through an antioxidant effect.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Oral mucositis is a common side-effect of chemotherapy and
radiotherapy. Moderate-to-severe mucositis occurs in virtually all
patients who receive radiotherapy for cancers of the head and neck
(1). Mucositis is a painful and debilitating side-effect of radio-
therapy for cancers of the head and neck (2). Radiotherapy can
cause erythematous, erosive and ulcerative mucositis, which can
result in a decrease in food intake. Swallowing difﬁculties are
associated with dehydration and weight loss. Furthermore, muco-
sitis reduces the quality of life (QOL) of patients because commu-
nication becomes very difﬁcult.
Local anesthetics, low-level laser irradiation, anti-ulcer agents,
and anti-inﬂammatory agents have been used for the treatment of
oral mucositis (3e6). However, the clinical response elicited by
these drugs against oral mucositis is poor.: þ81 89 960 5745.
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direct and indirect. In the ﬁrst type, X-rays ionize or excite mac-
romolecules in cells directly, leading to cell damage. In the second
type, X-rays excite water molecules in the cells and produce reac-
tive oxygen species (ROS), which damage cells. It has been found
that approximately 70% of the biological damage caused by X-rays
results from this indirect action (7). ROS such as the oxygen radical
(O2) and hydrogen peroxide (H2O2) are detoxiﬁed easily by anti-
oxidant defense enzymes, whereas cytotoxic ROS, such as the hy-
droxyl radical (OH), cannot be detoxiﬁed by these enzymes. During
radiotherapy, the detrimental effects of ionizing radiation on bio-
logical tissues such as the skin are mediated primarily by cytotoxic
ROS such as OH, which induces excess apoptosis (8).
Edaravone is a brain-protective agent used to treat acute
ischemic stroke. The mechanism of action of edaravone is based on
free-radical scavenging. The initial stage of radiation damage in-
volves formation of free radicals, and edaravone could be used to
help prevent lethal damage from ionizing radiation (9).
In the present study, we used mice for the evaluation of edar-
avone against radiation-induced oral mucositis (RIOM). Mice have
been used as an in vivomodel for RIOM (10, 11), so it is thought thatr B.V. All rights reserved.
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fect of edaravone on radiation damage in a mouse model (9, 12).
Edaravone has been reported to show a radioprotective effect if
given 30min before irradiation (9). In addition, it has been reported
that edaravone can suppress X-ray-induced apoptosis in hippo-
campal neurons (12). However, no study has evaluated the action of
edaravone against RIOM on the tips of the tongues of mice.
Therefore, we aimed to evaluate the effectiveness of edaravone
against RIOM in mice.
2. Materials and methods
The experimental protocol was conducted according to the
guidelines set by the Ethics Review Committee for Animal Experi-
mentation of Ehime University Medical School (Ehime, Japan).
2.1. Animals
Six-week-old ICR mice (30e40 g; Japan SLC Inc., Shizuoka,
Japan) were used in all experiments. Animals were housed in a
room maintained at 22 ± 2 C under a 12-h lightedark cycle with
lights on at 7:00 a.m. Mice were fed a standard rodent diet and had
free access to water.
2.2. RIOM
Mice (n ¼ 20 per group) were anesthetized (pentobarbital so-
dium, 50 mg/kg body weight, i.p.) and then irradiated. Mice had to
be irradiated only at the tip of the tongue, so the rest of the body
was shielded with a lead device (thickness, 0.5 mm). The tongue
was ﬁxed to the outer surface of the lead device using adhesive tape
and irradiated with a single radiation dose of 20 Gy. Radiation was
generated using a 150-kV potential (20 mA) X-ray source at a focal
distance of 350 mm hardened with a 1.0-mm aluminum ﬁltration
system (MBR-1520R-3; Hitachi, Tokyo, Japan). The rate of radiation
administration was 5.1 Gy/min.
2.3. Drugs
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one; Radicut®)
was provided by Mitsubishi Tanabe Pharma Corporation (Osaka,
Japan). A 2-Thiobarbituric Acid Reactive Substances (TBARS)
Microplate Assay kit was purchased from Funakoshi Corporation
(Tokyo, Japan).
2.4. Edaravone treatment
Edaravone was dissolved in a small volume of 1 M NaOH solu-
tion. The pHwas adjusted to 7with 1MHCL. The concentrationwas
adjusted to 3 mg/mL or 15 mg/mL in 0.9% (physiologic) saline so-
lution (9).
Body weight was recorded and tongues observed after irradia-
tion every day. Edaravonewas injected via the intraperitoneal route
30 min before irradiation. The control group was irradiated but
edaravone was not administered.
2.5. Assessment of mucositis
The scoring of oral mucositis was based on a modiﬁcation of the
method of Sonis et al. (13). To assess the severity of oral mucositis,
mice were anesthetized with isoﬂurane every day. The oral
mucositis score was: 0 ¼ normal; 1 ¼ partial hyperemia, erythema
and swelling; 2 ¼ overall hyperemia, erythema and swelling;
3 ¼ epidermolysis, hyperemia and erythema; 4 ¼ extensive epi-
dermolysis and bleeding; 5 ¼ bleeding and abscesses.2.6. Determination of myeloperoxidase (MPO) activity
MPO activity is a marker for neutrophils in inﬂamed tissue. MPO
activity wasmeasured inmouse tongues using amodiﬁcation of the
method of Chen et al. (14). After mice had been killed by cervical
dislocation 12 days after irradiation, tongue samples (n ¼ 10 per
group) were removed and stored at 70 C until required for assay.
Samples were weighed and homogenized in 10 volumes of 50 mM
potassium phosphate buffer (pH 6) containing 0.5% hexadecyl-
trimethylammonium bromide (SigmaeAldrich Japan, Tokyo, Japan)
for 1 min. After freezing and thawing homogenates thrice, they
were centrifuged at 10,000  g for 15 min at 4 C. Supernatants
were collected and reacted with 0.167 mg/mL o-dianisidine dihy-
drochloride (Wako Biochemicals, Osaka, Japan) and 0.0005% H2O2
(Wako Biochemicals) in 50 mM phosphate buffer (pH 6). MPO ac-
tivity was measured using a Microplate Reader (NJ-2300; Biotec,
Tokyo, Japan) at 450 nm. MPO activity was calculated by measuring
the slope of absorbance calibrated using MPO standards (Wako
Biochemicals) and expressed as MPO/g tongue.
2.7. Determination of TBARS levels
TBARS are present naturally in biological specimens. They
include lipid hydroperoxides and aldehydes, which increase in
concentration as a response to oxidative stress.
Tongue samples (n¼ 10 per group) were removed after mice had
been killed by cervical dislocation 12 days after irradiation, and
stored at70 C until required for assay. Samples were weighed and
homogenized in 0.5e1 mL of phosphate-buffered saline (PBS) per
100 mg of tongue. Samples were centrifuged at 1500  g for 10 min
at 4 C. Supernatants were collected and diluted in assay buffer.
TBARS levels were measured using the Microplate Reader
(Biotec) at 540 nm. TBARS levels were calculated by measuring the
slope of absorbance calibrated using TBARS standards (Funakoshi
Corporation, Tokyo, Japan) and expressed as TBARS/g tongue.
2.8. Histopathologic analyses
For evaluation of edaravone, tongues were removed for histo-
pathologic analyses after killing mice 12 days post-irradiation.
Specimens were ﬁxed in 10% neutral-buffered formalin, dehy-
drated and embedded in parafﬁn (Wako Biochemicals). Tissue
sections were obtained and stained with hematoxylin & eosin
(H&E) and examined under light microscopy (200magniﬁcation).
2.9. Immunohistochemical (IHC) detection
For evaluation of edaravone, tongues were removed for IHC an-
alyses after killing mice 12 days post-irradiation. We used parafﬁn-
embedded tissue sections for TUNEL staining (400 magniﬁca-
tion). At ﬁrst, we conducted deparafﬁnization, hydration and protein
digestion. Subsequently, we labeled the 3-terminal ends of DNAwith
100 mL (or 50 mL) of TdT Reaction Solution for 10 min at 37 C. We
washed sections with PBS, and labeled them with POD-conjugated
antibody. We undertook color development with 100 mL of 3,30-
Diaminobenzidine solution at room temperature for 5 min, washed
with double-distilled water, and then counter-stained. These actions
were followed by dehydration, cleaning, mounting and inspection
under a lightmicroscope.We counted the number of TUNEL-positive
cells on the tongue tips and expressed them as a percentage.
2.10. Statistical analyses
Results are the mean and standard error of the mean, or the
mean value. Datawere analyzed using one-way analysis of variance
Fig. 2. Time-course of survival after X-ray irradiation.
Fig. 3. Data are the mean ± SEM score of oral mucositis (n ¼ 10). Mice tongues were
irradiated with 20 Gy on day-0. *p < 0.05, signiﬁcantly different from the control value
(SteeleDwass test).
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ered signiﬁcant.
3. Results
3.1. Progress after irradiation
We measured body weight after irradiation every other day.
Irradiation of 20 Gy to the tongues of mice led to a decrease in body
weight that was maximal at day-12. After day-12, body weight
increased (Fig. 1). Intake of food and water also decreased, and was
accompanied by weight loss.
Fig. 2 shows the dose-dependency of edaravone (30 and
300 mg/kg). The number of mice that survived decreased after day-
12. A signiﬁcant difference in survival was not found. Behavioral
disorders were not observed in mice even at 300 mg/kg edaravone.
3.2. Pathophysiologic observations
Pathophysiologic changes in mouse tongues were evaluated by
macroscopic and histologic means. Fig. 3 shows the scoring for oral
mucositis. Oral mucositis was not observed for 7 days, but devel-
oped on day-8. The severity score reached a maximum value on
day-12. Thereafter, the score decreased with time. The oral muco-
sitis score for edaravone in the 300 mg/kg-administered group was
signiﬁcantly lower than that of the control group on day-10 and
day-12. Total scores between day-0 and day-12 for edaravone at 30
and 300 mg/kg were signiﬁcantly lower than those of the control
group, respectively (Fig. 4).
3.3. Histopathologic aspects
Histopathologic sections of tongue samples are shown in Fig. 5A.
In the control group, epidermolysis of the tongue was observed.
However, in the edaravone group, the degree of epidermolysis was
preserved, and inﬁltration of inﬂammatory cells decreased.
3.4. TUNEL staining
TUNEL staining was undertaken to conﬁrm cell injury due to
radiation. The control group had considerable apoptosis (23.7%
TUNEL-positive cells). In contrast, the percentage of TUNEL-positive
cells was decreased to 9.9% and 8.6% after treatment with 30 and
300 mg/kg of edaravone, respectively (Fig. 6).Fig. 1. Changes in body weight over time after X-ray irradiation. Each bar is the
mean ± SEM.3.5. MPO activity and TBARS levels
MPO activity and TBARS levels were measured 12 days after
irradiation. MPO activity in edaravone-administered groups at 30
and 300 mg/kg was signiﬁcantly lower compared with those in the
control group (Fig. 7).Fig. 4. Mean value of the total score of oral mucositis between day-0 and day-12 for
each group. Data are the mean ± SEM (n ¼ 10).*p < 0.05, signiﬁcantly different from
the control value (SteeleDwass test).
Fig. 5. Histologic photographs of tongue specimens after X-ray irradiation. Tongue specimens were ﬁxed with 10% buffered formalin and embedded in parafﬁn. A: Sections (3 mm)
were stained with hematoxylin and eosin (200). a: Intact, b: control (oral mucositis), c: edaravone 30 mg/kg, d: edaravone 300 mg/kg. B: Apoptotic cells were evaluated by TUNEL
staining (400). a: Intact, b: control (oral mucositis), c: edaravone 30 mg/kg, d: edaravone 300 mg/kg.
Fig. 7. Effect of edaravone on myeloperoxidase (MPO) activity (unit) in mouse tongues
submitted to oral mucositis. *p < 0.05, signiﬁcantly different from the control value
N. Nakajima et al. / Journal of Pharmacological Sciences 127 (2015) 339e343342TBARS levels in edaravone-administered groups at 30 and
300 mg/kg were lower than those of the control group, and edar-
avone (300 mg/kg) caused a signiﬁcant decrease compared with
that in the control group (Fig. 8).
4. Discussion
RIOM is a painful side-effect that can reduce QOL and lead to
discontinuation of cancer therapy, prolonged hospitalization, and
death. Oral mucositis is observed in almost all patients during
radiotherapy, but effective agents are lacking. In the present study,
the effect of edaravone against RIOM was investigated using ICR
mice.
In a study by Li et al. a single dose of 30 Gy to rats was employed,
and oralmucositis was observed (15). However, whenwe irradiated
30 Gy to mice tongues, mortality was high. Therefore, we used
20 Gy for our model of RIOM.
Food intake was decreased by the development of oral muco-
sitis, and body weight also decreased 8 days after irradiation. Loss
in body weight was maximal at day-12, but increased gradually
afterwards. Radiation exposure produced oral mucositis in all mice
from day-8. The oral mucositis score reached a maximum value at
day-12. Onset of oral mucositis was identical to the onset of oralFig. 6. Percentage apoptosis after TUNEL staining. *p < 0.05, signiﬁcantly different
from the control value (SteeleDwass test).mucositis observed after irradiation in human subjects, so we
considered our model to a suitable in vivo model of RIOM.
The effect of edaravone on epithelial cells was demonstrated
using H&E and TUNEL staining (Fig. 5A and B). In the control group,
mice tongues showed epidermolysis. Many inﬂammatory cells(SteeleDwass test).
Fig. 8. Effect of edaravone on determination of 2-Thiobarbituric Acid Reactive Sub-
stances (TBARS) activity (unit) in mouse tongues submitted to oral mucositis. *p < 0.05,
signiﬁcantly different from the control value (SteeleDwass test).
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administered group, the epithelial layer was retained and fewer
inﬂammatory cells were observed 12 days after irradiation. In
addition, many TUNEL-positive cells were observed in the control
group. Hence, cell injury from irradiation had occurred. Further-
more, we found that MPO activity in the edaravone-administered
group was lower than that of the control group. That is, inﬂam-
mation of mice tongues induced by radiation was ameliorated by
edaravone administration. These results showed that edaravone
was effective against RIOM.
In the present study, we focused on the antioxidant effects of
edaravone. Allopurinol is used mainly to treat chemotherapy-
induced mucositis, but has radical-scavenging activity against O2
only (16). Allopurinol inhibits release of xanthine oxidase, oroti-
dylate decarboxylase and proteases. It also shows an antioxidant
effect, consequently reducing the production of active oxygen (17).
Edaravone interacts biochemically with a wide range of free radi-
cals, donates electrons, and is transformed eventually to a stable
chemical (18). X-rays excite water molecules in cells and produce
ROS, which damage cells. The initial stage of radiation-induced
damage involves the formation of free radicals. Edaravone is ex-
pected to be effective in preventing lethal damage from ionizing
radiation (9) because it is a free-radical scavenger.
We alsomeasured TBARS levels because they tend to be increased
by radiation-induced oxidative stress. The control group had high
TBARS levels (i.e., the control group experienced high oxidative
stress). However, the edaravone-administered group exhibited slight
increases in TBARS levels. Sasano et al. reported that a higher dose of
edaravone completely eliminated intracellular generation of ROS by
X-rays (19). We conﬁrmed an antioxidant effect of edaravone against
RIOM. The effects of edaravone on oral mucositis seemweak, but the
antioxidant effects of edaravone are sufﬁcient. We considered
inﬂammation to be not only on a superﬁcial layer but alsowithin the
tongue. Hence, evaluation of only themacroscopic scorewasdifﬁcult.
Thedirect actionof radiationalso inﬂuences cell injury. Inﬂammation
and tissue injury are not suppressed only by antioxidant actions.
Damage to DNA can occur late after irradiation. By administering
edaravone, production of the initial free radicals due to irradiation
can be suppressed. Therefore, subsequent lipid peroxidation can also
be suppressed. The results shown in Fig. 8 suggest that edaravone can
suppress lipid peroxidation.
Several authors have reported on the antioxidant effects of
edaravone. Edaravone belongs to a class of pharmacologic agents
that reduce free radicals, and are associated with cholinergic
dysfunction and apoptotic damage (20). Combinations of antioxi-
dants have been shown to have synergistic anti-tumor effects
in vivo. Combinations of antioxidants with chemotherapy and ra-
diation have been shown to increase survival time and reduce
toxicity in humans (21). It has also been shown that the tumor
response to radiotherapy in patients with limited-stage prostate
cancer is not inhibited by concomitant naturopathic and nutritional
supplements based on the magnitude of the prostate-speciﬁc an-
tigen (PSA) response, the velocity of the PSA nadir, and the duration
of PSA normalization (22). These observations made us suspect that
edaravone does not inﬂuence the anti-tumor effect of radiation.
With regard to the points mentioned above, our results suggest
that the antioxidant effects of edaravone against RIOM are impor-
tant. Such effects warrant further investigation.
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